Trials / Terminated
TerminatedNCT02303158
Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression
Study of the Relationship Between Protein Biomarkers in Cerebrospinal Fluid and the Risk of Progression to Alzheimer&Apos;s Disease in a Cohort of Patients With Depression
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
It is currently accepted that depression during midlife is a risk factor for Alzheimer's disease (AD). Furthermore, several prospective population studies have demonstrated that depression is an independent risk factor for incident dementia of different types (e.g. vascular, mixed, Alzheimer's disease). However, it is not clear, what are the mechanisms that link depression and dementia, and if depression can be a prodromal manifestation of AD. There are also studies that suggest that depression could be an initial sign of AD. Objective: 1. Demonstrate that late life depression (over 60 years of age) constitutes the first manifestation of AD. 2. Define by rating scales and life stressors have differential risk profiles evolutionary AD. 3. To study the relationship between the subtypes of depression and CSF biomarkers, neurophycological test and evolution to AD.
Detailed description
Groups of subjects: patients with recent apparition of late life depression without fulfilling the dementia criteria (Global Deterioration Scale, GDS, stages 1, 2 and 3). A longitudinal, prospective population study with two years follow-up. A cohort of will be included in the study. The patient's depression will be defined and categorized according to its severity (Yesavage Scale), whether it's endogenous or reactive (Holmes and Rahe scale) and taking into account the patient's medical history of depression. There will be a prospective follow-up of conversion to dementia (starting from GDS Stage 4). It will be considered that dementia corresponds to AD if the biological markers of LCR present typical changes of AD at the moment of inclusion (Beta amyloid low and P-tau high). It will be studied if there's any correlation between the clinically defined depression types and a high risk of progression to dementia and especially to AD.
Conditions
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-02-01
- Completion
- 2018-10-01
- First posted
- 2014-11-27
- Last updated
- 2018-10-09
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02303158. Inclusion in this directory is not an endorsement.